Cisplatin Combination Chemotherapy Induces OxidativeStress in Advance Non Small Cell Lung Cancer Patients

Abstract

<b>Background:</b> This study determine oxidative stress and survival prospectively in advanced stage non smallcell lung cancer (NSCLC) patients following cisplatin based combination chemotherapy. Materials and <br/><b>Methods</b>:The oxidative stress levels (LPO, NO, GSH and SOD) of 144 control subjects and 203 advanced stage (IIIA/IIIB/IV) newly diagnosed NSCLC patients were assessed at pre-treatment (day ‘0’), and after the 3rd and 6th cyclesof chemotherapy. Groups were compared by repeated measures ANOVA while comparison of survival curveswas conduced by Kaplan-Meier methods. <br/><b>Results</b>: The pre-treatment mean levels of LPO and NO in patientswere significantly (P<0.01) higher while GSH and SOD were significantly (P<0.01) lower as compared to control.The oxidative stress was elevated more significantly (P<0.01) after the chemotherapy and was more evident inhigher stage than lower stage patients. The two year overall survival (%) of stage IV patients was significantlylower (P<0.05) as compared to stage III A and III B. The proportional mortality was also maximal in stage IVpatients (37.0%) followed by stage III B (31.7%) and III A (20.0%). <br/><b>Conclusion</b>: Cisplatin based combinationchemotherapy induces oxidative stress in NSCLC patients.